Trial Profile
A multicenter observational study of TAS-102 and regorafenib in patients with metastatic colorectal cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Nov 2016
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 27 May 2016 New trial record